Atlas Trials

Novo Nordisk A/S

1,385 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Novo Nordisk A/S

RecordFirmDate
Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine in Patients With Type 1 Diabetes (NCT00312104)Novo Nordisk A/S2002-04-01
Special Survey of Production of Insulin Aspart Specific Antibody (NCT01487369)Novo Nordisk A/S2002-04-01
Special Survey for Paediatric Subjects (NCT01487382)Novo Nordisk A/S2002-04-01
Special Survey for Type 1 or Type 2 Diabetic Patients (NCT01487408)Novo Nordisk A/S2002-04-01
Long Term Safety of Biphasic Insulin Aspart 30 in Juveniles With Type 1 Diabetes (NCT01486381)Novo Nordisk A/S2002-03-20
Comparison of Metformin, Repaglinide or the Combination of Both in Subjects With Type 2 Diabetes (NCT01465152)Novo Nordisk A/S2002-03-06
Safety and Efficacy of Insulin Aspart in Type 2 Diabetes (NCT01649570)Novo Nordisk A/S2002-03-01
Comparison of Insulin Detemir Plus Insulin Aspart With Insulin NPH Plus Human Soluble Insulin in Subjects With Type 1 Diabetes (NCT01486940)Novo Nordisk A/S2002-03-01
Efficacy and Safety of Activated Recombinant Human Factor VII in Severely Injured Trauma Patients (NCT01563523)Novo Nordisk A/S2002-03-01
Effect of Growth Hormone on Bone Mineral Density in Young Adults With Child-hood Onset Growth Hormone Deficiency (NCT00184678)Novo Nordisk A/S2002-02-01
Comparison of the Pharmacodynamics and Pharmacokinetics of Insulin Aspart and Human Insulin in Elderly People With Type 2 Diabetes (NCT00676819)Novo Nordisk A/S2002-01-10
Activated Recombinant Human Factor VII Following Cardiac Bypass Surgery for Paediatric Congenital Heart Disease (NCT01562574)Novo Nordisk A/S2002-01-01
Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes (NCT01527539)Novo Nordisk A/S2001-11-23
Effect of Repaglinide on Postprandial Lipemia in Type 2 Diabetes (NCT01605773)Novo Nordisk A/S2001-11-08
Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage (NCT01563445)Novo Nordisk A/S2001-11-01
Safety and Tolerability of Intravenous Doses of Activated Recombinant Human Factor VII in Healthy Volunteers (NCT01563471)Novo Nordisk A/S2001-10-01
Comparison of Liraglutide Inhaled Into the Lungs Compared to Liraglutide Injected Under the Skin in Healthy Male Volunteers (NCT01511159)Novo Nordisk A/S2001-10-01
Efficacy and Safety of Activated Recombinant Human Factor VII in Refractory Haemorrhagic Cystitis (NCT01561352)Novo Nordisk A/S2001-09-01
Frequency of Hypoglycaemic Episodes During Treatment With Insulin Detemir in Well Controlled Subjects With Type 1 Diabetes (NCT01697657)Novo Nordisk A/S2001-09-01
Trial of NovoSeven® in Haemophilia - Joint Bleeds (NCT00108797)Novo Nordisk A/S2001-09-01
Observational Study of NovoNorm® in Subjects With Diabetes (NCT01498913)Novo Nordisk A/S2001-08-30
Bleeding Profile With Continuous Hormone Replacement Therapy of Activelle® in Postmenopausal Women (NCT01705249)Novo Nordisk A/S2001-08-14
Controlled Study to Evaluate the Efficacy and Safety of the Treatment With Growth Hormone in Tibia Fractures (NCT00254514)Novo Nordisk A/S2001-08-01
Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII in Acute Intracerebral Haemorrhage (NCT01566786)Novo Nordisk A/S2001-08-01
Safety and Efficacy of Activated Recombinant Human Factor VII in Patients Undergoing Orthotopic Liver Transplantation (NCT01563458)Novo Nordisk A/S2001-08-01
Safety and Efficacy of Activated Recombinant Human Factor VII in Cirrhotic Patients Undergoing Partial Hepatectomy (NCT01562821)Novo Nordisk A/S2001-07-01
Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever (NCT01601613)Novo Nordisk A/S2001-07-01
Efficacy and Safety of Repaglinide Combined With Insulin NPH in Subjects With Type 2 Diabetes (NCT01562561)Novo Nordisk A/S2001-06-01
Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes (NCT01508949)Novo Nordisk A/S2001-06-01
Cardiovascular Effects on Growth Hormone Therapy in Adults With Growth Hormone Deficiency (NCT01698944)Novo Nordisk A/S2001-05-16
Safety and Efficacy of Somatropin in Children With Growth Hormone Deficiency (NCT01502124)Novo Nordisk A/S2001-05-08
Comparison of Single Dose and Steady State Pharmacodynamics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes (NCT01526941)Novo Nordisk A/S2001-05-01
Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 Diabetes (NCT01508923)Novo Nordisk A/S2001-05-01
Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen™ in Subjects With Type 2 Diabetes (NCT01704378)Novo Nordisk A/S2001-04-18
Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes (NCT01509742)Novo Nordisk A/S2001-04-01
Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Allogeneic Stem Cell Transplantation (NCT01562158)Novo Nordisk A/S2001-04-01
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent (NCT01511198)Novo Nordisk A/S2001-02-01
Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group (NCT01511185)Novo Nordisk A/S2001-02-01
Evaluation of the Efficacy and Safety of Insulin Detemir Compared With That of NPH Insulin in Subjects With Type 1 Diabetes. (NCT03220425)Novo Nordisk A/S2001-02-01
Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and 50 in Subjects With Type 2 Diabetes (NCT01620424)Novo Nordisk A/S2001-02-01
A Study Looking Into the Effect of NNC 55-0414 in Subjects With Type 2 Diabetes (NCT00400283)Novo Nordisk A/S2001-01-19
Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetes (NCT01467375)Novo Nordisk A/S2001-01-08
Pharmacokinetics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes (NCT01524809)Novo Nordisk A/S2001-01-01
Safety and Efficacy of Long-term Somatropin Treatment in Children (NCT01543867)Novo Nordisk A/S2001-01-01
Safety and Efficacy of Biphasic Insulin Aspart 50 in Subjects With Type 2 Diabetes (NCT01650129)Novo Nordisk A/S2000-12-13
Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency (NCT01563926)Novo Nordisk A/S2000-10-23
Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 Diabetes (NCT01509755)Novo Nordisk A/S2000-10-01
Effect of Growth Hormone in Children With Growth Hormone Deficiency (NCT00262249)Novo Nordisk A/S2000-08-01
Long Term Effect of Somatropin in Subjects With Intrauterine Growth Retardation (NCT01734447)Novo Nordisk A/S2000-04-30
A Single Dose Trial in Healthy Caucasians and Japanese Subjects Investigating the Pharmacokinetics of Somatropin (NCT00931476)Novo Nordisk A/S2000-04-06
Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Gestational Diabetes (NCT00065130)Novo Nordisk A/S2000-04-01
Comparison of Biphasic Human Insulin 30 With Biphasic Insulin Aspart in Subjects With Diabetes (NCT01520818)Novo Nordisk A/S2000-03-01
Pharmacokinetics of Biphasic Insulin Aspart 50 and 70 in Japanese Healthy Volunteers (NCT01620333)Novo Nordisk A/S2000-02-01
Examining the Long-term Safety of Insulin Aspart When Used as a Part of the Treatment for Type 1 Diabetes (NCT00832182)Novo Nordisk A/S1999-12-22
Comparison of Two Formulations of Biphasic Insulin Aspart 70 (NCT01523041)Novo Nordisk A/S1999-11-03
A Trial Investigating the Relationship Between Pharmacodynamic and Interstitial Concentration for Insulin Detemir and Human Insulin (NCT02162407)Novo Nordisk A/S1999-10-01
Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes (NCT01507311)Novo Nordisk A/S1999-09-01
Safety and Tolerability of Liraglutide in Healthy Volunteers and Subjects With Type 2 Diabetes (NCT01507285)Novo Nordisk A/S1999-08-01
Growth Hormone Treatment of Children Born With Retarded Intrauterine Growth at Age 2-5 Years (NCT00184691)Novo Nordisk A/S1999-04-01
Comparison of Biphasic Insulin Aspart (30, 50 and 70) and Insulin Aspart in Healthy Subjects (NCT01520831)Novo Nordisk A/S1999-04-01
Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors Under Normal Clinical Practice (NCT01579955)Novo Nordisk A/S1999-03-10
Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors When Undergoing Surgery (NCT01579968)Novo Nordisk A/S1999-03-10
Non-Interventional Study of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors (NCT01586936)Novo Nordisk A/S1999-03-10
Comparison of Two Biphasic Insulin Aspart Treatments in Subjects With Type 2 Diabetes (NCT01520753)Novo Nordisk A/S1999-03-01
Safety and Tolerability of Liraglutide in Healthy Male Volunteers (NCT01507272)Novo Nordisk A/S1999-03-01
Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients (NCT01562834)Novo Nordisk A/S1998-10-21
Induction of Puberty With 17-beta Estradiol in Girls With Turner Syndrome (NCT01710696)Novo Nordisk A/S1998-07-23
Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery (NCT01561391)Novo Nordisk A/S1998-04-01
Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or Type 2 Diabetes (NCT01467323)Novo Nordisk A/S1998-04-01
Growth Hormone Treatment in Infants Aged 1 to 2 Years With Chronic Renal Insufficiency (CRI) and Growth Retardation. (NCT00184769)Novo Nordisk A/S1998-01-29
Comparison of 2 NovoFine® Needles on the Reflux of Insulin (NCT00872560)Novo Nordisk A/S1998-01-20
Safety and Efficacy of Insulin Aspart in Subjects With Type 1 Diabetes (NCT01707134)Novo Nordisk A/S1997-09-01
Special Survey for Long Term Application (NCT01516229)Novo Nordisk A/S1997-05-01
Localisation of Potential Insulin Deposits in Normal Weight and Obese Diabetics Using 6 mm and 12 mm Long Needles (NCT00871416)Novo Nordisk A/S1997-04-09
Pharmacokinetics, Pharmacodynamics and Safety of Biphasic Insulin Aspart 30 in Type 2 Diabetes (NCT01697618)Novo Nordisk A/S1997-04-01
Growth Response in Girls With Turner Syndrome (NCT01734486)Novo Nordisk A/S1996-09-23
Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 in Healthy Volunteers (NCT01707160)Novo Nordisk A/S1995-11-01
Evaluation of Safety and Efficacy of 17-Beta Estradiol in Treatment of Atrophic Vaginitis: An Extension Trial (NCT00464971)Novo Nordisk A/S1995-01-31
Efficacy and Safety of 17-Beta Estradiol in Treatment of Atrophic Vaginitis (NCT00465192)Novo Nordisk A/S1994-08-31
Growth Hormone Treatment of Children Diagnosed of Intrauterine Growth Retardation (NCT01697644)Novo Nordisk A/S1990-10-01
Somatropin Effect on Linear Growth and Final Height in Subjects With Noonan Syndrome (NCT01529840)Novo Nordisk A/S1990-06-01
Comparison of Antibody Levels in Children and Adolescents After Initiation of Insulin Therapy by Either Insulin Aspart or Soluble Human Insulin (NCT00410033)Novo Nordisk A/S1989-12-01
Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome (NCT01518062)Novo Nordisk A/S1989-11-01
Use of Somatropin in Turner Syndrome (NCT01518036)Novo Nordisk A/S1987-09-14
Compassionate Use of Concizumab if You Have Haemophilia (NCT04921956)Novo Nordisk A/S
← Previous

Track Novo Nordisk A/S automatically

Every clearance here is in the API, with alerts when new ones post.